Photo od Ahmed Kotb
from daiichisankyo.us
Jun 22, 2025, 11:29
Ahmed Kotb: Choosing the Right DOAC For Your Patient?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“Choosing the right DOAC for your patient?
anticoagulant choice based on clinical profiles”
Elderly/Frail- Apixaban, Edoxaban
Obese -Apixaban or Rivaroxaban
CKD Apixaban, Edoxaban 30mg
GI Bleed Risk-Apixaban
Compliance issues- Edoxaban, Rivaroxaban
You can explore more detailed, evidence-based insights on individualized anticoagulant therapy at Hemostasis Today, your source for expert-guided approaches in thrombosis and hemostasis.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?